In various implementations, a composition comprising R-beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. The composition may include sodium R-beta-hydroxybutyrate salts; potassium R-beta-hydroxybutyrate; and one or more other salts of R-beta-hydroxybutyrate.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present invention relates to an antibacterial and biofilm formation-inhibiting composition containing myristoleic acid as an active ingredient, wherein the myristoleic acid has been confirmed to exhibit an antibacterial effect against acne bacterium (Cutibacterium acnes) and Staphylococcus aureus, which cause skin inflammation and trouble, and to effectively inhibit the biofilms of Cutibacterium acnes and Staphylococcus aureus, at a very low concentration, and thus, the composition containing myristoleic acid as an active ingredient can be provided as an antibacterial agent and an anti-biofilm composition, and can be provided as a cosmetic composition for ameliorating skin inflammatory diseases.

The present invention relates to an antibacterial and biofilm formation-inhibiting composition containing myristoleic acid as an active ingredient, wherein the myristoleic acid has been confirmed to exhibit an antibacterial effect against acne bacterium (Cutibacterium acnes) and Staphylococcus aureus, which cause skin inflammation and trouble, and to effectively inhibit the biofilms of Cutibacterium acnes and Staphylococcus aureus, at a very low concentration, and thus, the composition containing myristoleic acid as an active ingredient can be provided as an antibacterial agent and an anti-biofilm composition, and can be provided as a cosmetic composition for ameliorating skin inflammatory diseases.

The present invention relates to pharmaceutical oral dosage forms releasing compounds in specific parts of the small intestine of a subject, wherein said compounds stimulate enteroendocrine cells in the subject's jejunum and lower small intestine to release one or more enterokines. The present invention also relates to a method of producing such pharmaceutical oral dosage forms. The pharmaceutical oral dosage forms of the invention are particularly for use in the treatment and prevention of metabolic conditions or diseases, osteoporosis, malabsorption conditions, neurodegenerative diseases, conditions of impaired gastro-intestinal function and cardiovascular diseases.

The present invention relates to pharmaceutical oral dosage forms releasing compounds in specific parts of the small intestine of a subject, wherein said compounds stimulate enteroendocrine cells in the subject's jejunum and lower small intestine to release one or more enterokines. The present invention also relates to a method of producing such pharmaceutical oral dosage forms. The pharmaceutical oral dosage forms of the invention are particularly for use in the treatment and prevention of metabolic conditions or diseases, osteoporosis, malabsorption conditions, neurodegenerative diseases, conditions of impaired gastro-intestinal function and cardiovascular diseases.

It is disclosed a food mixture, in particular a food mixture comprising hydroxytyrosol, oleuropein, and soluble fibres. In particular, the present invention relates to a food mixture comprising: —a fraction (a) which comprises soluble fibres; —a powdered fraction (b) which comprises at least 100 mg/kg hydroxytyrosol and at least 250 mg/kg oleuropein where said amounts refer to said powdered fraction (b). Said food mixture finds application, moreover, in the preparation of bread, pasta, and baked goods in general. The invention also describes food products which contain this mixture, a process for the preparation thereof, as well as the uses thereof in human and animal nutrition, in the treatment and in the prevention of inflammatory conditions and in the reduction of postprandial glycaemia.

It is disclosed a food mixture, in particular a food mixture comprising hydroxytyrosol, oleuropein, and soluble fibres. In particular, the present invention relates to a food mixture comprising: —a fraction (a) which comprises soluble fibres; —a powdered fraction (b) which comprises at least 100 mg/kg hydroxytyrosol and at least 250 mg/kg oleuropein where said amounts refer to said powdered fraction (b). Said food mixture finds application, moreover, in the preparation of bread, pasta, and baked goods in general. The invention also describes food products which contain this mixture, a process for the preparation thereof, as well as the uses thereof in human and animal nutrition, in the treatment and in the prevention of inflammatory conditions and in the reduction of postprandial glycaemia.

The application provides a composition comprising cannadibiol, a fatty acid component comprising a balanced amount of omega-3 and omega-6 fatty acids, and a sterol and optionally a vitamin E compound. The composition has been shown to be well tolerated and supportive when administered to subjects suffering from or at risk of developing a skin disorder and/or an inflammatory condition, such as atopic dermatitis. Also disclosed are methods of supporting the immune system and skin health of a subject involving administration of the compositions.